直肠癌的非手术治疗是否可行？
Is Nonoperative Management of Rectal Cancer Feasible?
机构信息
Colorectal Unit, Department of Surgery, Complejo Asistencial Doctor Sótero del Río, Santiago, Región Metropolitana, Chile. Electronic address: https://twitter.com/ffquezad.
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue | SR-201, New York, NY 10065, USA.
出版信息
Adv Surg. 2023 Sep;57(1):141-154. doi: 10.1016/j.yasu.2023.05.001. Epub 2023 Jun 14.
Abstract
During the past decade, the treatment of locally advanced rectal cancer (LARC) has become more complex. Total neoadjuvant treatment (TNT) has increased the rates of both clinical and pathologic complete response, resulting in improved long-term oncological outcomes. The feasibility to implement nonoperative management (NOM) depends on solving current challenges such as how to correctly identify the best candidates for a NOM without compromising oncologic safety. NOM should be part of the treatment discussion of LARC, considering increasing rates of clinical complete response, potential quality of life gains, avoidance of surgical morbidity, and patient preferences.
摘要
在过去的十年中，局部晚期直肠癌（LARC）的治疗变得更加复杂。新辅助治疗（TNT）增加了临床和病理完全缓解的比例，从而改善了长期肿瘤学结果。实施非手术治疗（NOM）的可行性取决于解决当前的挑战，例如如何正确识别 NOM 的最佳候选者而不影响肿瘤学安全性。考虑到临床完全缓解率的提高、潜在的生活质量获益、避免手术发病率以及患者的偏好，NOM 应成为 LARC 治疗讨论的一部分。
相似文献
1
Is Nonoperative Management of Rectal Cancer Feasible?直肠癌的非手术治疗是否可行？
Adv Surg. 2023 Sep;57(1):141-154. doi: 10.1016/j.yasu.2023.05.001. Epub 2023 Jun 14.
2
Nonoperative Management for Rectal Cancer.直肠癌的非手术治疗。
Hematol Oncol Clin North Am. 2022 Jun;36(3):539-551. doi: 10.1016/j.hoc.2022.03.003. Epub 2022 May 11.
3
Nonoperative Management of Rectal Cancer: The Watch and Wait Strategy.直肠癌的非手术治疗：观察与等待策略。
Surg Oncol Clin N Am. 2022 Apr;31(2):171-182. doi: 10.1016/j.soc.2021.11.003. Epub 2022 Mar 9.
4
[Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].[局部晚期高危直肠癌患者新辅助综合治疗的疗效与安全性分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007.
5
[Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].[局部进展期中低位直肠癌新辅助治疗后完全缓解的合理评估：“观察等待”策略的利弊]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):507-513. doi: 10.3760/cma.j.issn.1671-0274.2019.06.002.
6
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.直肠癌的器官保留：一项II期随机对照试验，评估接受放化疗加诱导或巩固化疗以及全直肠系膜切除术或非手术治疗的局部晚期直肠癌患者的3年无病生存率。
BMC Cancer. 2015 Oct 23;15:767. doi: 10.1186/s12885-015-1632-z.
7
[Advances of optimized neoadjuvant therapy in the treatment of locally advanced rectal cancer].[优化新辅助治疗在局部晚期直肠癌治疗中的进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):527-533. doi: 10.3760/cma.j.issn.1671-0274.2019.06.005.
8
Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial.直肠癌患者的非手术治疗：从OPRA试验中吸取的经验教训。
Cancers (Basel). 2022 Jun 30;14(13):3204. doi: 10.3390/cancers14133204.
9
'Watch and wait' after chemoradiotherapy for rectal cancer.直肠癌放化疗后的“观察与等待”策略
ANZ J Surg. 2018 Sep;88(9):836-841. doi: 10.1111/ans.14352. Epub 2018 Jul 25.
10
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术：初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
引用本文的文献
1
Early prediction of histopathological response of locally advanced rectal cancer after 1 week of preoperative radiochemotherapy using FDG PET-CT imaging: a prospective clinical validation study.使用氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描（FDG PET-CT）成像对局部晚期直肠癌术前放化疗1周后组织病理学反应进行早期预测：一项前瞻性临床验证研究。
Radiat Oncol. 2025 Aug 1;20(1):121. doi: 10.1186/s13014-025-02703-x.
本文引用的文献
1
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.A022104/NRG-GI010 联盟：杰纳斯直肠癌试验：一项随机 II/III 期试验，旨在测试三联化疗与双联化疗在局部晚期直肠癌患者的临床完全缓解和无病生存方面的疗效。
BMC Cancer. 2024 Jul 26;24(1):901. doi: 10.1186/s12885-024-12529-7.
2
The Risk of Distant Metastases in Patients With Clinical Complete Response Managed by Watch and Wait After Neoadjuvant Therapy for Rectal Cancer: The Influence of Local Regrowth in the International Watch and Wait Database.新辅助治疗后采用观察等待策略管理的临床完全缓解直肠癌患者远处转移的风险：国际观察等待数据库中局部复发的影响
Dis Colon Rectum. 2023 Jan 1;66(1):41-49. doi: 10.1097/DCR.0000000000002494. Epub 2022 Oct 21.
3
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.直肠癌新辅助治疗反应的基因组和转录组决定因素。
Nat Med. 2022 Aug;28(8):1646-1655. doi: 10.1038/s41591-022-01930-z. Epub 2022 Aug 15.
4
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.直肠癌患者接受全新辅助治疗后的器官保存。
J Clin Oncol. 2022 Aug 10;40(23):2546-2556. doi: 10.1200/JCO.22.00032. Epub 2022 Apr 28.
5
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.放化疗联合诱导或巩固化疗作为局部晚期直肠癌患者的全新辅助治疗：CAO/ARO/AIO-12 随机临床试验的长期结果。
JAMA Oncol. 2022 Jan 1;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445. Epub 2022 Jan 20.
6
Watch and wait after a clinical complete response in rectal cancer patients younger than 50 years.对于 50 岁以下的直肠癌患者，在获得临床完全缓解后进行观察和等待。
Br J Surg. 2021 Dec 17;109(1):114-120. doi: 10.1093/bjs/znab372.
7
Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy.直肠癌患者接受全新辅助治疗后的器官保存。
Dis Colon Rectum. 2021 Dec 1;64(12):1463-1470. doi: 10.1097/DCR.0000000000002122.
8
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.局部晚期直肠癌新辅助治疗的应用：帕博利珠单抗在 2 期随机临床试验中的初步结果。
JAMA Oncol. 2021 Aug 1;7(8):1225-1230. doi: 10.1001/jamaoncol.2021.1683.
9
Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial.短程放疗后化疗的非手术直肠癌管理：一项非随机对照试验。
Clin Colorectal Cancer. 2021 Sep;20(3):e185-e193. doi: 10.1016/j.clcc.2021.03.003. Epub 2021 Apr 7.
10
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.局部晚期直肠癌患者的 FOLFIRINOX 新辅助化疗和术前放化疗（UNICANCER-PRODIGE 23）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.
Zotero 插件